V-Bio Ventures
VC Fund
Gent, Belgium
V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.
- Total investments:
- 44
- Last investment:
- Lead investor:
- 34%
- Fund size:
- $129M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries V-Bio Ventures invests in
Stages V-Bio Ventures invests in
Countries V-Bio Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Seed
- $3.1M–$50M
- Series A
- $6.6M–$70M
- Series B
- $12M–$88M
Investment Focus
Industry
- Biotechnology 16 (36%)
- Health Care 11 (25%)
- Therapeutics 9 (20%)
- Medical 8 (18%)
- Pharmaceutical 5 (11%)
Stage
- Series A 20 (45%)
- Series B 9 (20%)
- Seed 6 (14%)
- Funding Round 4 (9%)
- Series C 2 (5%)
Country
- Belgium 13 (30%)
- France 4 (9%)
- United States 2 (5%)
- United Kingdom 2 (5%)
- Italy 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Shelley Margetson
Managing Partner
|
Managing Partner | Total investments: 1 | Find email | |
Willem Broekaert
Managing Partner
|
Managing Partner | Total investments: 1 | Find email | |
Christina Takke
Managing Partner
|
Managing Partner | Total investments: 3 | Find email | |
Ward Capoen
Partner
|
Partner | Total investments: 8 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Step Pharma
|
Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe. | $44.3M / Series C / Oct 15, 2025 | |
Animab
|
Animal Health Company | $11.8M / Series B / Jul 01, 2025 | |
RootWave
|
RootWave is an electronics company that develops tools that kill weeds it enables farmers to control weeds on their farm. Its technology is an alternative substitute for herbicides and other weed control chemicals. The company was founded in 2012 and headquartered in Warwickshire, United Kingdom. | $12M / Jun 10, 2025 | |
Avidicure
|
Avidicure is pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality.“AVC-Boosters”, designed to safely deliver targeted and potent monotherapy, with broad applicability in oncology. | $50M / Seed / Apr 24, 2025 | |
Augustine Therapeutics
|
Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors and GABABR1a activators for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $83.9M / Series A / Mar 24, 2025 | |
ATB Therapeutics
|
ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients. | $57.2M / Series A / Nov 18, 2024 | |
Confo Therapeutics
|
Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations ofthese receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention. | $65.2M / Series B / Jul 26, 2024 | |
|
Augustine Therapeutics
|
Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors and GABABR1a activators for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $18.2M / Series A / Jun 26, 2024 | |
Biodol Therapeutics
|
Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (CyrilRivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics. | $7.6M / May 21, 2024 | |
Flindr Therapeutics
|
Immagene develops personalized cancer immunotherapies to fight multiple cancer type. | $21.4M / Series A / Apr 24, 2024 | |
| See all 44 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does V-Bio Ventures invest in?
V-Bio Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 44 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is V-Bio Ventures's check size?
V-Bio Ventures typically joins rounds of $3.1M–$50M at Seed, $6.6M–$70M at Series A and $12M–$88M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds V-Bio Ventures participates in.
How do I contact V-Bio Ventures?
Public channels for V-Bio Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at V-Bio Ventures?
The team at V-Bio Ventures includes Shelley Margetson (Managing Partner), Willem Broekaert (Managing Partner) and Christina Takke (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
